AI-Designed Drug Reverses Biological Aging Markers in Clinical Study
An artificial intelligence-designed drug candidate targeting idiopathic pulmonary fibrosis has demonstrated a simultaneous reduction in biological age across six internationally recognized proteomic clocks, according to a study published in Nature Biotechnology. Developed by Insilico Medicine in collaboration with researchers from Harvard Medical School, Stanford University, The Broad Institute, RWTH Aachen University, Peking University, and Westlake University, the Phase IIa clinical evaluation of the small-molecule inhibitor rentosertib marks a foundational shift in how biopharmaceutical firms approach aging biomarkers in standard clinical trials.
- Biological Age Reversal: Longitudinal serum proteomic data analyzed via six independent aging clocks showed a consistent reduction in predicted biological age among patients receiving rentosertib.
- Functional Lung Improvements: Patients in the 60-mg once-daily cohort experienced a mean improvement in Forced Vital Capacity (FVC) of +98.4 mL, contrasting with a mean decline of -20.3 mL in the placebo group.
- AI-Driven Discovery: The drug candidate targets TNIK, a kinase identified via generative AI platforms as a dual-purpose target implicated in both fibrosis and aging hallmarks.
Clinical Trial Design and Proteomic Findings
The peer-reviewed findings, detailed in Nature Biotechnology and supported by data deposited in the China National Center for Bioinformation (CNCB OMIX accession: OMIX008341), stem from a Phase IIa clinical trial assessing rentosertib in patients with idiopathic pulmonary fibrosis (IPF). Unlike traditional geroscience efforts that rely on repurposed generic compounds like metformin or rapamycin, Insilico Medicine utilized its generative chemistry platform, Chemistry42, to design a novel molecule specifically hitting the TNIK target. The target itself scored highly across six established hallmarks of aging during preclinical assessments.
During the Phase IIa trial (NCT05938920), published previously in Nature Medicine, researchers tracked Forced Vital Capacity, an essential measure of pulmonary function that typically declines with age. In healthy individuals over 65, FVC drops by 20 to 50 milliliters annually, paralleling the typical onset age of IPF. Trial results indicated a dose-dependent reversal in FVC decline for treated patients. By prospectively incorporating longitudinal serum proteomic screening into the trial protocol, investigators were able to evaluate biological age shifts alongside primary safety and efficacy endpoints.
Translating Biomarkers to Patient Care
The integration of proteomic aging clocks into standard therapeutic trials provides a practical framework for assessing geroprotective drugs. For individuals managing complex pulmonary conditions or seeking preventative evaluations, navigating these emerging diagnostic metrics requires specialized clinical oversight. Timely clinical assessment remains vital for identifying appropriate therapeutic interventions and aligning care protocols with current oncological and aging science standards.
The clinical data will be formally presented by first author Alex Zhavoronkov, founder and chief executive officer of Insilico Medicine, at the Nature conference: Redefining Healthcare in the Age of AI, hosted at Sorbonne University in Paris. As researchers continue to analyze longitudinal datasets, regulatory bodies and pharmaceutical developers are examining how proteomic endpoints can accelerate the timeline for longevity therapeutics moving toward later-stage evaluations. For clinical operations and research teams seeking to implement advanced biomarker tracking, partnering with verified clinical trial infrastructure and regulatory compliance specialists ensures adherence to evolving international standards.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice.